摘要
目的探讨自体外周血造血干细胞移植（auto-PBSCT）治疗急性白血病（AL）的临床疗效。方法回顾性分析第三军医大学大坪医院野战外科研究所2006年3月至2015年12月首次行auto-PBSCT治疗的急性白血病患者19例,其中急性髓细胞白血病（AML）12例,急性淋巴细胞白血病（ALL）7例;男10例,女9例,平均年龄39.4（16～64）岁。均在诱导缓解和巩固强化后,采集自体外周血干细胞并行auto-PBSCT,术后定期随访及维持治疗。结果 19例患者均获得造血功能重建,无一例发生移植相关死亡;12例AML患者平均随访时间38.3（9～93）个月,6例（50.0%）仍存活,6例（50.0%）持续完全缓解（CR）,3年总生存（OS）率50%（6/12）;7例ALL患者平均随访时间28.7（3～106）个月,4例（57.1%）存活,3例（42.9%）持续CR,3年OS率71.4%;所有患者的死亡均因白血病本病复发所致。结论 auto-PBSCT可提高AL患者的总生存（OS）率和无白血病生存（DFS）率,是无条件行异基因造血干细胞移植（allo-HSCT）的AL患者可供选择的一个治疗方案。
Objective To investigate the clinical efficacy of autologous peripheral blood stem cell transplantation（auto-PBSCT）for adult patients with acute leukemia（AL）.Methods The retrospective analysis was conducted in 19 AL cases of primary auto-PBSCT from March of 2006 to December of 2015 in Daping Hospital of Third Military Medical University,which consisted of 12 cases of acute lymphoblastic leukemia（AML）and 7cases of acute myeloid leukemia（ALL）.There were 10 males and 9females,with an average age of 39.4.All the patients received auto-PBSCT after the induced remission and the consolidated and intensified therapy.The clinical follow-ups were performed.Results The hematopoiesis recovered in all the 19 patients and there was no transplantation-related death.The average follow-up time of the 12 AML patients was 38.3 months.The overall survival rate was 50%and all the 6survivors were still in continuous complete remission（CR）.The average followup time of the 7ALL patients was 28.7months.The overall survival rate was 57.1% and 3survivors out of 4still lived with continuous CR.All the death was caused by leukemia relapse.Conclusion The overall and leukemia-free survival rate of the patients with acute leukemia can be improved by auto-PBSCT.Therefore,auto-PBSCT can be an alternative treatment for patients who are incapable of being treated with allogeneic hematopoietic stem cell transplantation.
出处
《成都医学院学报》
CAS
2016年第2期201-205,共5页
Journal of Chengdu Medical College
关键词
急性白血病
自体外周血造血干细胞移植
维持治疗
疗效
Acute leukemia
Autologous peripheral blood stem cell transplantation
Maintenance treatment
Efficacy
